Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "How safe are the biologicals in treating asthma and rhinitis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: How safe are the biologicals in treating asthma and rhinitis? | BioMed Central Allergy Asthma Clinical Immunology Open Access How safe are the biologicals in treating asthma and rhinitis Linda S Cox Address Department of Medicine Nova Southeastern University Osteopathic College of Medicine Fort Lauderdale Florida USA Email Linda S Cox-Lindaswolfcox@msn.com Published 22 October 2009 Received I October 2009 Allergy Asthma Clinical Immunology 2009 5 4 doi 10.1186 1710-1492-5-4 Accepted 22 October 2009 This article is available from http www.aacijournal.com content 5 1 4 2009 Cox licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract A number of biological agents are available or being investigated for the treatment of asthma and rhinitis. The safety profiles of these biologic agents which may modify allergic and immunological diseases are still being elucidated. Subcutaneous allergen immunotherapy the oldest biologic agent in current use has the highest of frequency of the most serious and life-threatening reaction anaphylaxis. It is also one of the only disease modifying interventions for allergic rhinitis and asthma. Efforts to seek safer and more effective allergen immunotherapy treatment have led to investigations of alternate routes of delivery and modified immunotherapy formulations. Sublingual immunotherapy appears to be associated with a lower but not zero risk of anaphylaxis. No fatalities have been reported to date with sublingual immunotherapy. Immunotherapy with modified formulations containing Th1 adjuvants DNA sequences containing a CpG motif CpG and 3-deacylated monophospholipid A appears to provide the benefits of subcutaneous immunotherapy with a single course of 4 to 6 preseasonal injections. There were no serious treatment-related adverse events or anaphylaxis in the .